Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Salicylhydroxamic acid is a small molecule drug that acts as a potent and irreversible inhibitor of the urease enzyme in various bacteria and plants. It is primarily used for urinary tract infections due to its ability to disrupt bacterial metabolism by competitively inhibiting urease, an enzyme essential for certain pathogens. The compound is structurally similar to urea but cannot be hydrolyzed by urease, leading to metabolic disruption in susceptible organisms. Salicylhydroxamic acid also exhibits trypanocidal activity and inhibits alternative oxidase (AOX) in some plants, fungi, and protists. When administered orally, it is metabolized into salicylamide, which has analgesic, antipyretic, and anti-inflammatory properties[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on salicylhydroxamic acid.